Harshamitra Super Speciality Cancer Centre & Research Institute Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 24-10-2024
- Paid Up Capital ₹ 0.10 M
as on 24-10-2024
- Company Age 9 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.17 Cr
as on 24-10-2024
- Revenue -74.31%
(FY 2023)
- Profit -449.97%
(FY 2023)
- Ebitda -141.74%
(FY 2023)
- Net Worth -16.88%
(FY 2023)
- Total Assets -27.79%
(FY 2023)
About Harshamitra Super Speciality Cancer Centre & Research Institute
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.17 Cr.
Govindaraj Ganesan and Sasipriya Ponniah serve as directors at the Company.
- CIN/LLPIN
U74999TN2015PTC100693
- Company No.
100693
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 May 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Tiruchirappalli, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Harshamitra Super Speciality Cancer Centre & Research Institute?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Govindaraj Ganesan  | Director | 28-May-2015 | Current |
| Sasipriya Ponniah | Director | 28-May-2015 | Current |
Financial Performance of Harshamitra Super Speciality Cancer Centre & Research Institute.
Harshamitra Super Speciality Cancer Centre & Research Institute Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 74.31% decrease. The company also saw a substantial fall in profitability, with a 449.97% decrease in profit. The company's net worth observed a substantial decline by a decrease of 16.88%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Harshamitra Super Speciality Cancer Centre & Research Institute?
In 2023, Harshamitra Super Speciality Cancer Centre & Research Institute had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Harshamitra Oncology Private LimitedActive 10 years 7 monthsGovindaraj Ganesan and Sasipriya Ponniah are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 02 May 2018 | ₹1.17 Cr | Open |
How Many Employees Work at Harshamitra Super Speciality Cancer Centre & Research Institute?
Harshamitra Super Speciality Cancer Centre & Research Institute has a workforce of 15 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Harshamitra Super Speciality Cancer Centre & Research Institute, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Harshamitra Super Speciality Cancer Centre & Research Institute's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
